港股異動 | 中集安瑞科(3899.HK)漲近6% 前三季度收益升46% 新簽訂單增長44.9%
格隆匯10月19日丨中集安瑞科(3899.HK)高開高走,現漲近6%,報10.22港元,總市值207億港元。中集安瑞科公佈,截至2021年9月30日止9個月,公司收益合計128.49億元人民幣,同比增長46%。期間新簽訂單合計139.16億元,同比增長44.9%。於2021年9月30日,公司在手訂單合計124.82億元,同比增長18.4%。受益於行業需求旺盛以及疫情在全球範圍逐步得到控制,集團2021年第三季度收益大幅上升41.1%至人民幣49.09億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.